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Background: Decision making in cancer treatment is influenced by standardized RECIST measurements which are
subjective to interobserver variability. Aim of this pilot study was to evaluate whether it is feasible to transfer the
radiologist’s task of RECIST measurements to a trained radiology physician assistant and whether this influences
diagnostic performance.
Methods: 177 lesions in twenty patients were measured on baseline and two follow-up CTs using RECIST 1.1: Arm
A according to routine clinical practice where various radiologists read scans of the referred patients. Arm B according
to the experimental setting where a radiology physician assistant performed RECIST measurements of target lesions
defined by the radiologists on baseline scans. Performance and agreement were compared between groups.
Results: Standard deviation between lesion measurements of arm A and B was four millimeters. Interobserver
agreement comparing response category classification was substantial, ĸ = 0.77 (95% CI: 0.66 - 0.87). Sensitivity and
specificity for the radiology physician assistant for assessing progressive disease were 100% (95% CI: 61% - 100%) and
94% (95% CI: 81% - 98%) respectively.
Conclusion: RECIST measurements performed by a paramedic are a feasible alternative to standard practice. This could
impact the workflow of radiological units, opening ways to re-assigning radiologists’ important, standardized but time
consuming tasks to paramedics.
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Radiological unit workflowBackground
Evaluation of tumor burden with imaging plays an
important role in the clinical assessment of response to
cancer therapy and subsequent treatment decision as
well as in clinical trials to evaluate the effect of new
drugs. Assessment of disease progression will influence
the decision on whether or not the treatment should be
discontinued. Reduction in tumor size and volume is a
marker of treatment effect in early phase therapeutic
trials. Response assessment by imaging methods hence
needs to be highly reproducible and accurate.* Correspondence: anni.sailer@mumc.nl
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unless otherwise stated.Guidelines recommend lesion size measurements fol-
lowing standardized methods such as WHO criteria [1]
and RECIST 1.0 [2]. Recently the RECIST committee in-
troduced a new version of Response Evaluation Criteria
In Solid Tumors: RECIST 1.1 [3,4]. Following these
criteria, a total number of up to five target lesions are
chosen to follow-up during and after therapy. Up to two
lesions per organ, with a minimum long axis of diameter
ten millimeters in solid lesions and fifteen millimeters in
lymph nodes in an axial plane should be identified and
measurements compared to prior assessment [5,6].
Solid tumor assessment following the RECIST criteria
is now standard both in clinical practice and trial set-
tings, mostly practiced on CT chest and/or CT abdomen.
In trial settings, measurements are performed by trialtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that, in daily clinical routine, scans of the individual
patient are often evaluated by several radiologists at dif-
ferent time points along the treatment and only very
rarely handled by the same reader. Previous studies have
shown inaccuracy in assessment due to considerable
interobserver variability in measurements [7-13]. Incon-
sistency in measurements can lead to incorrect inter-
pretation in tumor response. A prior study advocated
a restriction in the number of radiologists analyzing
RECIST scans in order to prevent interobserver vari-
ation and misinterpretation [8]. Our hypothesis is that
RECIST 1.1 measurements of lesions on response evalu-
ation CTs – a highly relevant but time consuming task
of the radiologist - are as accurate and probably more
consistent in the hands of specialized radiology phys-
ician assistants as in that of several radiologists handling
one individual patient’s scans along his treatment. If this
can be confirmed, transferring RECIST routine mea-
surements to radiology physician assistants could not
only potentially increase cost efficiency but also free the
time of radiologists whose responsibilities as sparring
partner in the multidisciplinary cancer management
team are increasing.
The aim of this study was to compare the assessment
of tumor burden performed by various board certified
radiologists (the common clinical setting of RECIST CT
evaluation) to the assessment performed by a trained
CT radiology physician assistant.
Methods
This retrospective study was approved by the local ethics
committee (Medisch-ethische toetsingscommissie (METC
aZM/UM)) as a quality control pilot study without further
need for informed consent.
The study group consisted of twenty patients. Inclu-
sion criteria were: (1) patients with proven solid tumors,
(2) treatment with anti-neoplastic therapy, (3) RECIST
1.1 as principle evaluation criteria of tumor response, (4)
CT baseline and follow-up studies performed between
2009 and 2011.Figure 1 Type of target lesions in group of patients (left image) andEight patients had colorectal cancer, seven patients
had renal cancer, three patients had breast cancer, one
had an ovary carcinoma and one had pancreatic cancer.
The mean age of the patients was 61 ± 10 years and the
mean follow-up time during the study was seven months.
Figure 1 gives detailed overview on target lesions.
CT scans were performed with the same protocol,
contrast-enhancement, five millimeter slice thickness and
were evaluated in standard lung, abdominal and liver
window.
In all patients CTs of the chest and/or abdomen were
performed on a baseline before therapy started as well as
two times for follow-up during and after anti-neoplastic
therapies.
Image evaluation
Study consisted of two evaluation arms: Arm A presen-
ting the standard clinical practice where various board
certified radiologists read the scans of the patients ad
random. As in usual practice none of them attempted to
only read the follow-up CTs of those patients for whom
they have evaluated the baseline CT. In other words one
patient’s set of CTs could have been evaluated by several
radiologists, but all were specialized in abdominal im-
aging. The radiologist who evaluated the baseline CT
defined target lesions following the RECIST 1.1 criteria.
Arm B: a radiology physician assistant with CT experience
of more than ten years read and assessed all follow-up CT
scans. The target lesions at baseline CT were indicated by
the radiologists but their RECIST measurement not
revealed to the assistant. The physician assistant re-
measured the lesions both on baseline and follow-up
CTs. Figure 2 shows a scheme of the study design.
Fifty-nine target lesions were defined by the radiolo-
gists. A total of 177 target lesion measurements in twenty
patients were performed by both groups during the study
period.
Measurements of each lesion on each time point were
compared between the two study arms. Following the
RECIST 1.1 criteria, response categories consisting of sta-
ble disease (SD), complete response (CR), partial responsenumber of selected target lesions per patient (right image).
Figure 2 Study design.
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between the arm A and B. This was performed on two
time points, at follow-up 1 and 2.
All CT images where archived and reviewed in the in-
stitution’s Picture Archiving and Communication System
PACS, (Carestream Health Inc., Rochester, NY, USA).
Tumor size was measured by electronic calipers.
Statistical analysis
Interclass correlation coefficient was used to compare
the measurements of the physician assistant to standard
clinical practice and prediction intervals were constructed
by means of a linear regression model. A Bland-Altman
plot was performed for illustration of differences in mea-
surements. Taken tumor assessment performed by the
radiologists as the standard of reference, sensitivity andFigure 3 Prediction intervals by linear regression model (left) and Blaspecificity of detecting progressive disease by the assistant
were analyzed. Kappa statistics was applied to evaluate
agreement concerning response category classification
between the physician assistant and standard clinical
practice. Statistical analyses were performed using SPSS
Statistics 20.0 (SPSS, Chicago IL, USA).
Results
Comparison of the 177 lesion measurements between
the two study arms by means of linear regression model
and Bland-Altman plotting is shown in Figure 3.
Taken the radiologists’ measurements as the reference
standard, the linear regression model shows the predic-
tion of the radiologists’ results for the measurement per-
formed by the assistant. Regression coefficient was R2 =
0.924. Interclass correlation coefficient between arm And-Altman plot (right). N = 177.
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limeters for both arms. Standard deviation between arm
A and B for all 177 lesion measurements was four milli-
meters, which was 18% of the mean lesion size. Consid-
ering only differences between the radiologist and the
assistant’s measurement greater than two millimeters,
there was a concordance in assessment of 70% of all
measurements.
According to RECIST 1.1 criteria, the measurements
of arms A and B were used to judge tumor burden and
classify into response categories. Interobserver agree-
ment concerning category classification between arm A
and B was substantial, ĸ = 0.77 (95% CI: 0.66 - 0.87). The
physician assistant did not underestimate response ca-
tegory. In four cases there was an overestimation of
response category by the assistant. Table 1 shows the
agreement concerning progressive disease, partial re-
sponse, stable disease and complete response for the
two study arms.
Sensitivity for detecting progressive disease (PD) for the
physician assistant (B) was 100% (95% CI: 61% - 100%),
specificity was 94% (95% CI: 81% - 98%), respectively.
Discussion
Response assessment by imaging before and during
cancer therapy influences clinical decision making on
whether or not therapy should be continued. The role of
the radiologist is consolidated and his task is threefold.
He needs to confirm the presence or absence of new
suspicious lesions, rule out any acute threatening condi-
tions such as impeding fracture or spinal cord compres-
sion and assess the overall tumor burden and predict
whether or not there is a response by measuring changes
in tumor size during therapy. For the latter, RECIST 1.1
criteria are widely adopted in standard clinical practice.
Most of the RECIST assessment is based on CT images.
These target lesion measurements need to be accurate
and reproducible. Such measurements are time consum-
ing, especially because the baseline or previous follow-
up CT scans of the individual patient are not necessarilyTable 1 Comparison of the two arms regarding tumor
responses at follow-up 1 and follow-up 2 according to
RECIST 1.1 measurements
Arm A: radiologists
CR PR SD PD Total
Arm B: CR 0 0
Physician assistant PR 3 3
Assistant SD 2 27 29
PD 2 6 8
Total 0 5 29 6 40
Notes: CR: Complete Response, PR: Partial Response, SD: Stable Disease,
PD: Progressive Disease.read by one and the same radiologist and are often han-
dled by several radiologists along the treatment. Therefore
these measurements are known to be prone to significant
interobserver variability [7-13]. This matter of lack of
consistency has already successfully been addressed in trial
settings, where measurements are widely performed by
trial radiologists. However, in routine clinical practice, on-
cologists are often confronted with inconsistent measure-
ments of lesions at consecutive follow-up scans.
Therefore there is a need to improve the assessment
of treatment response evaluation by imaging in clinical
routine. Our hypothesis is that RECIST 1.1 routine mea-
surements of lesions on consecutive CTs can be as
accurate and probably more consistent in the hands of
dedicated radiology physician assistants, who read all
surveillance CTs of one individual patient, as in that of
several radiologists handling one individual patient’s
scans along his treatment.
We believe that transferring of these routine tasks
from the radiologists to dedicated and trained radiology
physician assistants will reduce interobserver variability,
improve consistency and contribute to a more time and
cost efficient diagnostic workflow. Introducing parame-
dic assistants supporting the daily task of physicians is a
well accepted phenomenon at many clinical units. Multi-
disciplinary teams have recognized the benefit in time
and cost-efficiency if nurse/physician assistants support
their daily practice in outpatient clinics and on hospital
wards. Although so far radiologists have been more
reluctant to involve paramedics in the diagnostic making
process, it is inevitable that reorganization of radiolo-
gical units needs to happen should the high quality of
care be met without further increasing the costs. In
current oncological radiology practice there is a huge
demand on the radiologists involved in multidisciplinary
decision making. His attendance is expected at multi-
disciplinary cancer meetings and his responsibilities are
extending beyond reading and reporting images. Inter-
action with clinicians is as important as evaluation of
images, but hiring more radiologists to cover all the
workload would not be a realistic, certainly an expensive
solution. Thus it will be necessary to reorganize and to
find ways to free the radiologists’ time without com-
promising diagnostic outcome.
To our knowledge this is the first study evaluating
whether transferring the task of RECIST lesion measure-
ments by radiologists to CT experienced radiology phys-
ician assistants could affect diagnostic performance and
outcome.
The results of our pilot study are promising showing
high agreement between the radiologists’ and the radi-
ology physician assistant’s performance. Sensitivity for
detecting progressive disease (PD) for the assistant was
100% and specificity was 94% respectively. There was no
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According to RECIST guidelines, three measurements
were performed within each patient at different time
points implying serial dependency of the data. This is a
limitation due to the study design. Furthermore, this
pilot study is based on a restricted number of patients
and observations, which is why outcome should be eval-
uated in a larger setting. However, results show that in-
volving paramedic assistants in the diagnostic workflow
does not necessarily compromise outcome, if this hap-
pens with well-trained physician assistants and under
close monitoring by a radiologist.
In our study, target lesions were defined by radiolo-
gists on the baseline scan and information was passed to
the radiology physician assistant including key images,
image number and lesion location and measurements.
A potential detection of new lesions by the radiologist
assistant was not evaluated. In this way the diagnostic
decision making remained the responsibility of the radi-
ologist. We believe that such an approach guarantees
the high quality of standard care. In this respect we also
think that the paramedic should work side by side with
the radiologist in the reporting unit, so that – whenever
necessary - the radiologist, who is responsible for au-
thorizing the report, is at easy reach for consultation.
We recognize that physician assistants are not trained
to diagnose. This is a responsibility that should remain
with radiologists. In our opinion, definition of target le-
sions, detection of new lesions as well as critical lesions
should be part of the diagnostic task assigned to the
radiologist, in order to assure reliability. Hence our read-
ing design. We are aware that in this way, the radiolo-
gist’s time will still be consumed by reviewing and
approving the assistant’s findings. In the first phase of
implementation of the new workflow, additional supervi-
sion (and education) of the assistant will require an add-
itional time investment from the radiologist and it might
be that in this phase the radiologist would have been
more efficient if he would do the evaluation solely. How-
ever, after a learning curve and with increasing experi-
ence of a well-trained assistant, actual time needed for
supervision is expected to rapidly decrease. Based on
our experience, lesion measurements and comparison of
each lesion measurement with that of previous scans
was in fact the most time consuming part of RECIST
evaluation. Re-assignment of this task in routine practice
to a trained physician assistant is therefore expected
to be time efficient in the long run. Nevertheless, dedi-
cated cost-effectiveness analysis of this approach has yet
to happen.
Conclusion
In conclusion, we believe that the approach of transfer-
ring target lesion measurements to radiology physicianassistants could, besides reducing the measurement vari-
ability, hold benefits in terms of time efficiency and allow
radiologists to focus on addressing more complex diag-
nostic dilemmas and on interactions with clinicians. As-
suming a lower cost of radiology assistant’s manpower,
this approach is also suspected to be cost-efficient. The
results from our pilot study - if confirmed in further
larger prospective studies - will therefore potentially im-
pact clinical practice.
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